Feed DFPH
Summary
21 / 100 · Bulios Score
Valuation 0Growth -Profitability 6Quality 10Debt 94Stability 0
What speaks for it
- It holds more cash than debt: $373.6K against $90.2K.
What to watch
- The company made a loss over the last 12 months.
- It passes only 1 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $475.3K.
Profitability in detailIs it financially healthy?
YesCash and short-term investments $1.12M
Debt $90.2K
Free cash flow over 12 months -$461.4K
Over the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Health Care, Patient Service 50%
- Fee For Service 32%
- Capitated Revenue 17%
- Clinical Research Trials And Other Revenue 1.0%
By region
The company reports no revenue by region.
Health Care, Patient Service brings in 50% of revenue.
Segments in detail